A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Clinical trial NCT05976568 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT05976568
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-09-01
- Primary completion
- 2027-09-01
- Enrollment
- 668
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.